Scientists preserve breast tissue in gel for personalized cancer drug testing

A team of researchers at the University of Manchester has figured out how to keep human breast tissue alive outside the body for at least a week—a discovery that could reshape how doctors develop and test cancer drugs. The breakthrough, published in the Journal of Mammary Gland Biology and Neoplasia and funded by the Prevent Breast Cancer charity, uses a special gel solution called VitroGel to preserve tissue in a way that maintains its structure, its cell types, and its ability to respond to medications exactly as it would inside a living patient.

Until now, scientists testing new breast cancer drugs have relied on animal models and simplified laboratory cultures that cannot fully replicate the complexity of human tissue. These older approaches lack the extracellular matrix, the supporting tissue structures, and the immune cells that actually influence how drugs work in real bodies. The result has been a pipeline clogged with drugs that look promising in the lab but fail when tested in actual patients. Dr. Hannah Harrison, the research fellow who led the work, explained that the new method opens a door to something far more precise: testing drugs directly on living human tissue to see which ones will work best for which women.

The implications are particularly significant for women at high genetic risk. Some carry mutations in the BRCA genes or have strong family histories of breast cancer, and they face difficult choices about prevention. Multiple drugs exist that can reduce their risk, but not all of them work equally well for every woman. With this new approach, doctors could take tissue from a patient, expose it to different drug candidates in the lab, and measure which one has the most beneficial effect on her particular biology. "Ultimately, this means that women can take the most effective drug for their particular genetic makeup," Harrison said. The method also allows researchers to study how breast density—a known risk factor for cancer—responds to different hormones and chemicals, potentially revealing new insights into cancer development itself.

The research addresses a longstanding bottleneck in drug development. Scientists have struggled to identify promising new treatments partly because the models available to them are too crude. Animal testing, while useful, does not always translate to human outcomes. Cell cultures grown in dishes lack the three-dimensional architecture and cellular diversity of real tissue. By preserving actual human breast tissue and keeping it viable for extended periods, researchers can now conduct experiments that are far more representative of what happens in a patient's body. This should reduce the number of drugs that fail in clinical trials and accelerate the path from laboratory discovery to treatments that actually help people.

The timing matters. In the United Kingdom alone, nearly 56,000 women are diagnosed with breast cancer each year, according to Cancer Research UK. Globally, breast cancer is the second most common cancer, accounting for 11.6 percent of all newly diagnosed cases. Yet the picture is not entirely bleak. Survival rates have improved dramatically over the past two decades. Women diagnosed with early-stage breast cancer are now 66 percent less likely to die from the disease than they were 20 years ago, according to research from the University of Oxford. About 76 percent of breast cancer patients survive for at least 10 years.

Lester Barr, a consultant breast surgeon and founder of Prevent Breast Cancer, called the discovery "a hugely exciting development in animal-free research." He noted that while mortality from breast cancer has declined in the UK thanks to better screening and treatment, the number of diagnoses continues to rise. That makes the development of new prevention and risk-reduction options urgent, especially for women whose genetics or family history puts them at elevated risk. The ability to test drugs with greater accuracy in the laboratory should mean fewer failures in clinical trials and, ultimately, better outcomes for patients. The work represents a shift toward personalized medicine—the idea that treatment and prevention should be tailored to each person's unique biology rather than applied as a one-size-fits-all approach. What happens next depends on how quickly this technique can be scaled up and integrated into the drug development process, but the foundation has been laid.